Currently out of the existing stock ratings of Kumaraguru Raja, 14 are a BUY (100%).

Kumaraguru Raja

Work Performance Price Targets & Ratings Chart

Analyst Kumaraguru Raja, currently employed at BROOKLINE, carries an average stock price target met ratio of 26.19% that have a potential upside of 38.32% achieved within 115 days.

Kumaraguru Raja’s has documented 24 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CYCC, Cyclacel Pharmaceuticals at 07-Mar-2023.

Wall Street Analyst Kumaraguru Raja

Analyst best performing recommendations are on ARCT (ARCTURUS THERAPEUTICS HOLDINGS).
The best stock recommendation documented was for VERU (VERU) at 12/11/2020. The price target of $17 was fulfilled within 60 days with a profit of $10.64 (167.3%) receiving and performance score of 27.88.

Average potential price target upside

of $10.64 (167.3%) on VERU (VERU).
of $42.66 (34.5%) on ARCT (ARCTURUS THERAPEUTICS HOLDINGS).

ARCT Arcturus Therapeutics Holdings FBRX Forte Biosciences VERU Veru SCYX Scynexis CLBS Caladrius Biosciences ADIL Adial Pharmaceuticals DRMA Dermata Therapeutics EDSA Edesa Biotech CYCC Cyclacel Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ed Arce (HC WAINWRIGHT)